We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

Back to rankings

5 hedge funds and large institutions have $39K invested in Northwest Biotherapeutics, Inc. Common stock in 2020 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

95% more capital invested

Capital invested by funds: $20K → $39K (+$19K)

0% more funds holding

Funds holding: 5 → 5 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
+$1K
2
MSAM
Moloney Securities Asset Management
Missouri
+$344

Top Sellers

Rank Fund Capital Flow
1
MPI
Mairs & Power Inc
Minnesota
-$2K

NWBO Hedge Fund Activity: Q2 2020 in Review

5 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q2 2020, worth a combined $39K — up 95% from $20K a quarter earlier.

Fund positioning in NWBO was balanced in Q2 2020: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was CAPTRUST Financial Advisors, opening a new position worth an estimated $1K. The largest seller was Mairs & Power Inc, exiting entirely with an estimated $2K sold.

  • 5 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q2 2020, unchanged from Q1 2020.
  • Funds reported $39K of Northwest Biotherapeutics, Inc. Common stock stock for Q2 2020, up 95% quarter-over-quarter.
  • 1 fund opened new Northwest Biotherapeutics, Inc. Common stock positions in Q2 2020 and 1 closed out, a net change of 0 holders.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q2 2020 was CAPTRUST Financial Advisors, an estimated $1K added.
  • The largest Northwest Biotherapeutics, Inc. Common stock seller in Q2 2020 was Mairs & Power Inc, an estimated $2K sold.

Based on aggregated 13F filings for Q2 2020.